Breast Cancer

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Icro Meattini, ​MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

Panelists discuss how to choose among therapeutic options when multiple molecular alterations are detected, identify patient populations better suited to specific therapies, and share their excitement about potential advances in the HR+/HER2– breast cancer space.

Panelists discuss adverse events associated with antibody-drug conjugates (ADCs) that impact clinical decision-making and share strategies for managing these adverse events.

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.

Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.

For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.